Cx Precision Medicine

Cx Precision Medicine is a private, pre-revenue diagnostics company founded in 2019 and based in San Diego. Its core offering is the NeuroFirst™ platform, which uses proprietary algorithms to analyze blood protein biomarkers, aiming to rule out neurodegenerative disorders like Alzheimer's and Parkinson's at the primary care level. The company's technology is licensed from the research of Dr. Sid O'Bryant at the University of North Texas Health Science Center, positioning it to address critical gaps in early diagnosis and patient triage. CxPM is preparing to launch its first test while developing a pipeline of additional neurodegenerative diagnostic tools.

AI/ML-driven platform analyzing blood-based protein biomarkers (proteomics) to develop rule-out diagnostic tests for neurodegenerative diseases.

Highly competitive with established players like Roche, Quanterix, and C2N Diagnostics, all advancing blood-based biomarker tests for Alzheimer's. CxPM's differentiation lies in its specific 'rule-out' focus for the primary care setting and its proprietary AI algorithm trained on a large proteomic dataset.